QR kód

Dapagliflozin alleviates myocardial ischemia/reperfusion injury by reducing ferroptosis via MAPK signaling inhibition

Reperfusion is essential for ischemic myocardium but paradoxically leads to myocardial damage that worsens cardiac functions. Ferroptosis often occurs in cardiomyocytes during ischemia/reperfusion (I/R). The SGLT2 inhibitor dapagliflozin (DAPA) exerts cardioprotective effects independent of hypoglyc...

Celý popis

Uloženo v:
Hlavní autoři: Weixiang Chen, Yue Zhang, Zuoxiang Wang, Mingyue Tan, Jia Lin, Xiaodong Qian, Hongxia Li, Tingbo Jiang
Médium: Artigo
Jazyk:Inglês
Vydáno: Frontiers Media S.A. 2023-02-01
Edice:Frontiers in Pharmacology
Témata:
myocardial ischemia/reperfusion
dapagliflozin
ferroptosis
MAPK pathway
treatment
On-line přístup:https://www.frontiersin.org/articles/10.3389/fphar.2023.1078205/full
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Podobné jednotky